ArticleThe Lancet regional health. Western Pacific2025
Persistent lymphatic filariasis transmission seven years after validation of elimination as a public health problem: a cross-sectional study in Tonga.
Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Multi-pathogen serosurveillance in Tonga examining demographic correlates and geographic clustering of 17 pathogens.Scientific reports · 2026Article
- Integrated surveillance for lymphatic filariasis and other infectious diseases with a nationwide non-communicable disease STEPwise survey in the small Pacific Island Nation of Niue, 2025.Scientific reports · 2026Article
- Comparison of an integrated versus stand-alone approach to post-validation surveillance for lymphatic filariasis in Niue: a micro-costing study, 2025.Journal of global health · 2026Article
- Enablers of Post-Validation Surveillance for Lymphatic Filariasis in the Pacific Islands: A Nominal Group Technique and Expert Elicitation.Tropical medicine and infectious disease · 2026Article
- Integrated Approaches to Surveillance of Lymphatic Filariasis and Other Infectious Diseases in the Pacific Islands.Tropical medicine and infectious disease · 2026Article
- Article
- Global Lymphatic Filariasis Post-Validation Surveillance Activities in 2025: A Scoping Review.Tropical medicine and infectious disease · 2026Review
- Barriers and Facilitators to Implementing Post-Validation Surveillance of Lymphatic Filariasis in Pacific Island Countries and Territories: A Conceptual Framework Developed from Qualitative Data.Tropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The World Health Organization (WHO) has validated 21 countries as having eliminated lymphatic filariasis (LF) as a public health problem. Post-validation surveillance (PVS) is required in countries where LF has been eliminated. Tonga eliminated LF in 2017, but no PVS strategy has been established. We aimed to identify any persistent LF transmission in Tonga in 2024 and provide evidence to support a PVS strategy. Methods: A four-pronged, targeted, cross-sectional study was conducted in the Tongan districts of Tongatapu, Ha'apai, and Ongo Niuas in May-July 2024 in communities, primary schools, high schools, and an outpatient clinic. Participants were tested for LF antigen (Ag) and microfilariae (Mf). The outcome measure for persistent LF transmission was Ag-positivity. Findings: Between 9 May and 19 July 2024, 1787 participants were recruited from 12 communities, 11 primary schools, five high schools, and one outpatient clinic. Overall, 39 participants (2·2%) were Ag-positive and five (0·3%) were Mf-positive. The highest Ag prevalence was in communities (4·0%; 95% confidence interval [95%CI]: 2·9-5·6), where all Mf-positives (n = 5) were identified. Ag-positivity was associated with male sex (adjusted odds ratio [aOR]:4·86; 95%CI: 2·25-10·46), older age (>50 years vs 5-10 years [aOR:7·51; 95%CI: 2·13-26·47]), and residing in Ha'apai (aOR:15·08; 95%CI: 5·41-42·05) and Ongo Niuas (aOR:10·85; 95%CI: 3·91-30·08). Interpretation: We found persistent LF transmission in Tonga seven years post-validation. Community surveillance yielded the highest Ag and Mf prevalence. Efficiency of PVS could be improved by integrating surveillance activities into the existing health system and conducting community-based surveys, particularly among older males and in high prevalence areas. Funding: Task Force for Global Health, Bill & Melinda Gates Foundation, and the United States Agency for International Development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.